Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Oncology Molecular Diagnostics Market Set To Climb From $6.34 Billion In 2026 To $10.13 Billion By 2030
The oncology molecular diagnostics market has experienced significant expansion in recent years. This market is projected to grow from $5.65 billion in 2025 to $6.34 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 12.2%. Historically, this growth can be attributed to factors such as the increasing prevalence of cancer, the adoption of PCR and sequencing technologies, enhanced oncology research funding, the expansion of hospital diagnostic capabilities, and regulatory approvals for molecular tests.
The size of the oncology molecular diagnostics market is projected for significant expansion over the coming years. It is anticipated to reach $10.13 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 12.4%. This projected expansion during the forecast period is fueled by factors such as the embrace of precision oncology, progress in liquid biopsy techniques, the need for customized treatments, AI-powered data analysis, and deeper market penetration in developing regions. Key developments anticipated during this timeframe involve an increase in companion diagnostics, greater reliance on liquid biopsy, the broader implementation of biomarker-based testing, more extensive cancer screening initiatives, and the imperative for prompt and precise cancer identification.
Get A Free Sample Report With In-Depth Market Insights:
Oncology Molecular Diagnostics Market Growth Drivers: What’s Behind The Acceleration?
The growing need for personalized medicine is anticipated to fuel the expansion of the oncology molecular diagnostics market moving forward. Personalized medicine describes an innovative method in medical care and treatment that adapts medical choices, practices, interventions, and drug therapies to each specific patient. Oncology molecular diagnostics play a vital role in personalized medicine for cancer patients by offering tailored treatment plans, improved drug selection, and more precise, efficacious, and individualized treatment approaches, thereby enhancing patient results and overall quality of life. For instance, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit organization, reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, an increase from six in 2022. Therefore, the rising demand for personalized medicine is a key driver for the growth of the oncology molecular diagnostics market.
Oncology Molecular Diagnostics Market Segment Trends And Revenue Contributors
The oncology molecular diagnostics market covered in this report is segmented –
1) By Product: Instruments, Reagents, Other Products
2) By Technology: Polymerase Chain Reaction (PCR), In-Situ Hybridization (ISH), Isothermic Nucleic Acid Amplification Technology (INNAT), Chips And Microarrays, Sequencing, Mass Spectroscopy, Transcription Mediated Amplification (TMA), Other Technologies
3) By End User: Hospitals, Diagnostic Centers, Academic And Research Institutes, Other End Users
Subsegments:
1) By Instruments: Polymerase Chain Reaction (PCR) Machines, Sequencers, Microarray Platforms, Fluorescence In Situ Hybridization (FISH) Instruments
2) By Reagents: DNA And RNA Extraction Kits, PCR Reagents And Kits, NGS Library Preparation Kits, Diagnostic Assay Reagents
3) By Other Products: Software For Data Analysis And Interpretation, Quality Control And Calibration Products, Consumables, For Molecular Testing, Biomarkers For Oncology Testing
Oncology Molecular Diagnostics Market Trends: What’s Defining The Industry’s Next Phase?
Leading companies in the oncology molecular diagnostics market are concentrating on evolving genomics technologies, including next-generation cancer genome sequencing, computational analytics, and innovative tumor modeling, to enhance early cancer detection, identify mutations, and refine personalized treatment strategies. These advancements improve diagnostic accuracy, reduce processing times, and cater to the increasing need for localized, high-accuracy molecular testing. An illustration of this is OncoHelix-CoLab, a Canada-based precision oncology provider focused on genomic and immunologic profiling, advanced molecular diagnostics, and immune-profile testing, which inaugurated a cutting-edge laboratory at Burjeel Medical City in the UAE in May 2024. This facility, a result of a collaboration between Burjeel Holdings and OncoHelix, bolsters regional diagnostic capabilities by enabling complex molecular and immunology tests to be performed locally, thus eliminating the need to send them abroad. Among its specialized services are advanced assays for various cancers, including prostate cancer, further supported by partnerships such as its collaboration with Nanostics for the ClarityDX Prostate test.
Oncology Molecular Diagnostics Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the oncology molecular diagnostics market are F. Hoffmann-La Roche AG, Bayer AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthcare AG, Becton Dickinson and Company, Agilent Technologies Inc., HTG Molecular Diagnostics Inc., Hologic Inc., Illumina Inc., bioMérieux SA, Beckman Coulter Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corp., Bio-Techne Corporation, OPKO Health Inc., Myriad Genetics Inc., Guardant Health AMEA, Veracyte Inc., Adaptive Biotechnologies Corp., Foundation Medicine Inc., Pacific Biosciences of California Inc., NanoString Technologies Inc., Genomic Health Inc.
View The Full Oncology Molecular Diagnostics Market Report:
Oncology Molecular Diagnostics Market Regional Breakdown: Where Is Demand Concentrated?
North America was the largest region in the oncology molecular diagnostics market in 2025. Western Europe was the second largest region in the global oncology molecular diagnostics market report. The regions covered in the oncology molecular diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model